Systemic Therapy for Lung Cancer Brain Metastases

[1]  K. Hoeflich,et al.  1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC , 2020 .

[2]  E. Cho,et al.  CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Edward S. Kim,et al.  Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Serafino Pantano,et al.  First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study , 2017, The Lancet.

[5]  A. Drilon,et al.  PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers , 2019, Journal of Thoracic Oncology.

[6]  Ping Wang,et al.  Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO) , 2020 .

[7]  A. Shaw,et al.  Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial. , 2019, The Lancet. Oncology.

[8]  G. Scagliotti,et al.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[9]  K. Syrigos,et al.  Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227 , 2020 .

[10]  Robert T. Jones,et al.  Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.

[11]  N. Lin,et al.  Management of brain metastases according to molecular subtypes , 2020, Nature Reviews Neurology.

[12]  C. Grah,et al.  Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. , 2021, Clinical lung cancer.

[13]  S. Montgomery,et al.  Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases , 2017, bioRxiv.

[14]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[15]  H. Groen,et al.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[16]  P. Jänne,et al.  Five‐Year Survival in EGFR‐Mutant Metastatic Lung Adenocarcinoma Treated with EGFR‐TKIs , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  C. Marosi,et al.  ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. , 2013, Lung cancer.

[18]  Keunchil Park,et al.  Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. , 2019, Lung cancer.

[19]  P. Brastianos,et al.  Brain metastasis , 2019, Nature Reviews Cancer.

[20]  A. Drilon,et al.  Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.

[21]  P. V. Van Schil,et al.  Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  T. Mitsudomi,et al.  Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy , 2020, Translational lung cancer research.

[23]  H. Shih,et al.  Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. , 2018, International journal of radiation oncology, biology, physics.

[24]  S. Gettinger,et al.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  H. Shiraishi,et al.  Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. , 2020, Japanese journal of clinical oncology.

[26]  P. Li,et al.  Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study , 2020, Cancer Immunology, Immunotherapy.

[27]  L. Sequist,et al.  First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  P. Brastianos,et al.  Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues , 2014, Acta Neuropathologica.

[29]  M. Forster,et al.  Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited) , 2020, British Journal of Cancer.

[30]  Edward S. Kim,et al.  Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  Paul Baas,et al.  Liquid Biopsy for Advanced Non‐Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[32]  D. Galetta,et al.  Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis , 2021, Clinical and Translational Oncology.

[33]  J. Fang,et al.  OA01.08 A Phase I Study to Evaluate Safety and Antitumor Activity of BPI-7711 in EGFRM+/T790M+ Advanced or Recurrent NSCLC Patients , 2019, Journal of Thoracic Oncology.

[34]  R. Labet.  [Brain metastasis]. , 1957, Bulletin medical.

[35]  C. Bettegowda,et al.  Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[36]  S. Gettinger,et al.  A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[37]  P. Jänne,et al.  MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Novello,et al.  Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  N. Girard,et al.  Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. , 2018, European journal of cancer.

[40]  Julie L. Yang,et al.  Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label Trial. , 2020, JAMA oncology.

[41]  G. Galli,et al.  Uncommon targets in non-small cell lung cancer: everyone wants a slice of cake. , 2021, Critical reviews in oncology/hematology.

[42]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[43]  Alexander Radbruch,et al.  Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) , 2017, Neuro-oncology.

[44]  A. Shaw,et al.  First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. , 2020, The New England journal of medicine.

[45]  N. Magné,et al.  Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status , 2020, Journal for ImmunoTherapy of Cancer.

[46]  Chia-Chi Lin,et al.  Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Nechushtan,et al.  Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. , 2016, Lung cancer.

[48]  Keunchil Park,et al.  Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. , 2018, The Lancet. Oncology.

[49]  J. Ahn,et al.  Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  Ying Cheng,et al.  Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. , 2020 .

[51]  T. Mitsudomi,et al.  Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. , 2016, The Lancet. Oncology.

[52]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[53]  A. Zheng,et al.  Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors. , 2019, European journal of medicinal chemistry.

[54]  M. Ladanyi,et al.  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.

[55]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[56]  W. Weichert,et al.  Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  M. Stockler,et al.  CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC). , 2020 .

[58]  N. Yeh,et al.  Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Jänne,et al.  Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies , 2018, Cancer.

[60]  A. Scherpereel,et al.  Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. , 2018, Lung cancer.

[61]  D. Carbone,et al.  Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. , 2020 .

[62]  Yi-long Wu,et al.  Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial , 2019, EBioMedicine.

[63]  E. Smit,et al.  Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies. , 2021, Cancer treatment reviews.

[64]  A. Chella,et al.  Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial , 2019, Clinical Cancer Research.

[65]  Sung Sook Lee,et al.  Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study. , 2020 .

[66]  R. Mathijssen,et al.  Clinically relevant drug interactions with multikinase inhibitors: a review , 2019, Therapeutic advances in medical oncology.

[67]  A. Shaw,et al.  Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. , 2018, The Lancet. Oncology.

[68]  J. Lai-Kwon,et al.  Moving beyond Epidermal Growth Factor Receptor resistance in metastatic non-small cell lung cancer - a drug development perspective. , 2021, Critical reviews in oncology/hematology.

[69]  Steven D Chang,et al.  Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases , 2021, Journal of Neuro-Oncology.

[70]  E. Tan,et al.  Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases , 2018, BMC Cancer.

[71]  A. Iafrate,et al.  Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. , 2017, JCO precision oncology.

[72]  Lucio Crinò,et al.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  J. Ahn,et al.  Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[75]  Young Hak Kim,et al.  Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial , 2017, The Lancet.

[76]  N. Reinmuth,et al.  ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. , 2020, Annals of Oncology.

[77]  Susan M. Chang,et al.  Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications , 2019, Neuro-oncology.

[78]  R. Mathijssen,et al.  Clinical implications of food-drug interactions with small-molecule kinase inhibitors. , 2020, The Lancet. Oncology.

[79]  K. Kiura,et al.  The effect of nivolumab treatment for central nervous system metastases in non-small cell lung cancer. , 2017 .

[80]  S. Kannan,et al.  Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non–small cell lung cancer (NSCLC) with brain metastases , 2020, European Journal of Clinical Pharmacology.

[81]  M. Shingyoji,et al.  Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations , 2015, International Journal of Clinical Oncology.

[82]  James B. Yu,et al.  Local tumor response and survival outcomes after combined stereotactic radiosurgery and immunotherapy in non-small cell lung cancer with brain metastases. , 2020, Journal of neurosurgery.

[83]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[84]  S. Heo,et al.  Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. , 2020, Cancer discovery.

[85]  D. Planchard,et al.  Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  J. Schuetz,et al.  Obstacles to Brain Tumor Therapy: Key ABC Transporters , 2017, International journal of molecular sciences.

[87]  R. Camidge,et al.  A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov Trial Registry , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[88]  P. Jänne,et al.  CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[89]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[90]  D. Moro-Sibilot,et al.  Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study , 2017, Oncotarget.

[91]  L. Landi,et al.  Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. , 2019, European journal of cancer.

[92]  G. Barnett,et al.  The Impact of Sequencing PD-1/PD-L1 Inhibitors and Stereotactic Radiosurgery for Patients with Brain Metastasis. , 2019, Neuro-oncology.

[93]  M. Guan,et al.  Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases , 2019, Targeted Oncology.

[94]  G. Quéré,et al.  MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases , 2018, Journal of Thoracic Oncology.

[95]  A. Vortmeyer,et al.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[96]  L. Garraway,et al.  Oncogenic and drug sensitive NTRK1 rearrangements in lung cancer , 2013, Nature Medicine.

[97]  Nicholas D. Camarda,et al.  Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma , 2020, Nature Genetics.

[98]  Luhua Wang,et al.  Comparison of up-front radiotherapy and TKI with TKI alone for NSCLC with brain metastases and EGFR mutation: A meta-analysis. , 2018, Lung cancer.

[99]  Jie Yang,et al.  Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[100]  Weidong Wei,et al.  Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy , 2015, Oncotarget.

[101]  P. Yadav,et al.  Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. , 2020, Clinical lung cancer.

[102]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  T. Si,et al.  Detection of circulating tumor DNA from non‐small cell lung cancer brain metastasis in cerebrospinal fluid samples , 2020, Thoracic cancer.

[104]  Yi-long Wu,et al.  Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[105]  N. Girard,et al.  OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC) , 2017 .